No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CDNA240517C17500
- 0.30
- -0.05-14.29%
15min DelayTrading May 14 09:30 ET
0.30High0.30Low
0.30Open0.35Pre Close1 Volume2 Open Interest17.50Strike Price30.00Turnover148.46%IV15.55%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier3DDays to Expiry0.30Time Value100Contract SizeAmericanOptions Type0.2385Delta0.1349Gamma51.35Leverage Ratio-0.1017Theta0.0003Rho12.25Eff Leverage0.0048Vega
Intraday
- 5D
- 1D
News
Raymond James Downgrades CareDx to Market Perform From Outperform
Raymond James Downgrades CareDx to Market Perform From Outperform.
Express News | CareDx Inc : Raymond James Cuts to Market Perform From Outperform
Navigating 5 Analyst Ratings For CareDx
Throughout the last three months, 5 analysts have evaluated CareDx (NASDAQ:CDNA), offering a diverse set of opinions from bullish to bearish.The table below summarizes their recent ratings, showcasing
Express News | Raymond James Downgrades CareDx to Market Perform
CareDx Cut to Market Perform by Raymond James Over Valuation
Express News | Goldman Sachs Maintains Buy on CareDx, Raises Price Target to $14
Comments
Investors may believe CareDx's strong revenue growth is not imminent, leading to a low P/S ratio. Expected future revenue decline could further decrease the P/S ratio, making a significant stock price rise unlikely.
Little Excitement Around CareDx, Inc's (NASDAQ:CDNA) Revenues As Shares Take 28% PoundingDespite a strong price move, CareDx's P/S ratio still trails the industry. The low P/S is due to the forecast for sliding revenue. Without significant change, drastic rise in the stock is unlikely.
$CareDx(CDNA.US$ 4.80 missed and ran 📈👀
$CareDx(CDNA.US$ Check out these highlights! ((. Reported revenue of $67.2 million, an increase of 7% over the second
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
quarter of 2023, excluding approximately $7.8 million related to Medicare
claims billing that were held over from the first quarter of 2023 and
recognized in second quarter 2023 revenue.
-- Grew Testing Services patient results to 38,400, an increase of 2%
compared to the second quarter of 2023.
-- Achieved revenue of $9.9 million for Digital Solut...
1
Read more